A Colorado-based biotechnology company has applied for federal authorization to manufacture marijuana, marijuana extracts and THC as part of a new Food and Drug Administration (FDA)-regulated drug program involving whole-plant cultivation, clinical trials and research.
According to a Drug Enforcement Administration (DEA) notice made available for public inspection today, October 30, AJNA Biosciences, based in Littleton, Colorado, submitted its application on September 30. The notice is scheduled for publication in the Federal Register on November 2.
The application covers three categories of Schedule I controlled substances: marijuana extracts (drug code 7350), marijuana (7360) and tetrahydrocannabinols (7370).
The DEA filing states that AJNA plans to manufacture these substances and establish a new FDA-regulated drug program involving the cultivation of whole-plant marijuana. The company intends to use the material for internal research, clinical trials and analytical purposes, while also producing marijuana-derived substances for sale and distribution to customers.
The filing does not identify specific medical conditions the company intends to study, the clinical trials it plans to conduct or the quantities of marijuana it expects to produce. It also does not indicate that the FDA has approved any resulting drug products.
AJNA has previously pursued federal authorization to manufacture other Schedule I substances. In June 2025, the DEA published an application from the company to manufacture psilocybin and psilocyn for research and clinical trials. The agency subsequently granted that registration, according to a DEA notice dated December 18, 2025. Another application involving those substances was published in April 2026.
The newly disclosed application would expand the company’s federally regulated manufacturing activities into marijuana and its derivatives, subject to DEA approval.
Under federal regulations, companies seeking to manufacture Schedule I substances must obtain DEA registration and comply with requirements governing security, recordkeeping and the handling of controlled substances. Marijuana cultivation for research is subject to additional federal controls, including DEA oversight of production and distribution.
The October 30 notice provides a 60-day period following its November 2 publication during which registered bulk manufacturers of the affected substances and eligible applicants may submit objections or request a hearing.
The application does not constitute authorization to begin manufacturing marijuana under the proposed registration. If approved, the company’s activities would be limited to those authorized by the DEA, and any resulting pharmaceutical products would remain subject to applicable FDA requirements.










